Screener Summaries Updates Institutions Sign In More Updates › Financing › BDRX Financing · Jun 30, 2026
Biodexa Pharmaceuticals PLC entered into a securities purchase agreement on June 29, 2026, for a registered direct… BDRX Biodexa Pharmaceuticals Plc
Biodexa Pharmaceuticals PLC entered into a securities purchase agreement on June 29, 2026, for a registered direct offering and a concurrent private placement, alongside a warrant inducement. The transactions, expected to close on July 1, 2026, are expected to generate approximately $3.54 million in gross proceeds. The company is a pharmaceutical company focused on developing and commercializing therapeutic products.
More from Biodexa Pharmaceuticals Plc Biodexa enrolls 100th patient in Phase 3 Serenta trial for FAP, accelerating futility analysis timeline Oct 14, 2026 Biodexa announces one-for-eight reverse ADS split effective Oct 26 Oct 8, 2026 Biodexa Pharmaceuticals entered into a warrant inducement agreement on September 14, 2026, with an accredited holder… Sep 15, 2026 Biodexa Pharmaceuticals PLC reported unaudited interim results for the six months ended June 30, 2026 Sep 11, 2026 Biodexa Pharmaceuticals PLC shareholders approved a one-for-10,000 reverse stock split effective July 30, 2026… Jul 29, 2026 All content on this site is for informational purposes only and does not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. Always consult a qualified financial advisor before making investment decisions.
Financial data is obtained from public filings and third-party providers and is provided “as-is” without any guarantee of accuracy, completeness, or timeliness.
© 2026 go-intrinsic.com. All rights reserved.
